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In the introduction to their paper on the reporting of blinding in trial publications, 
Bello et al. [1] write that compromised blinding has raised concerns and, as 
examples, refer to studies on zinc lozenges and vitamin C for the common cold 
[2-4]. 
In 1975, Karlowski et al. [2] concluded from their vitamin C and common 
cold trial that “the effects [of ascorbic acid] demonstrated might be explained 
equally well by a break in the double blind”. The placebo consisted of lactose, 
which is easily distinguishable from ascorbic acid by taste. Statisticians and 
clinical trialists have frequently cited the Karlowski study in textbooks, the 
CONSORT statement [5], and other publications as an example of the placebo 
effect in action. In 1996, however, I showed in this journal that the Karlowski 
report contained erroneous analysis [6]. For example, 42% of the common cold 
episodes were missing from the comparison of the “blinded” vs. “unblinded” 
participants even though Karlowski presented those two groups as if they were 
complementary. Karlowski's placebo-effect explanation also contains several other
problems [6,7]. Over two dozen trials with valid placebos, such as citric acid, have
clearly shown that the effects of vitamin C on the common cold are not placebo 
effects [8]. Because the benefits of vitamin C demonstrated in the Karlowski trial 
are consistent with those observed in other studies, the Karlowski trial should not 
be claimed as an example of placebo effect in action.
In 1984, Eby et al. reported that therapeutically administered zinc gluconate 
lozenges significantly shortened the duration of colds [3]. In this journal, Farr and 
Gwaltney proposed that the apparent benefit of zinc lozenges in the Eby trial may 
have resulted from the placebo effect, since the lozenges may have tasted bad [4]. 
However, Farr and Gwaltney provided no evidence that bad taste  shortens the 
duration of colds. A dozen trials have examined the effect of zinc lozenges on the 
duration of the common cold [9]. Five studies with the lowest doses of zinc 
uniformly found no benefit, whereas three trials with high doses of zinc in the 
form of acetate found a 42% (95% CI 35% to 48%) reduction in the duration of 
colds and five studies with high doses of zinc in the form of other salts found a 
20% (95% CI 12% to 28%) reduction. Depending on their composition, zinc 
gluconate lozenges can taste bad with time, whereas zinc acetate lozenges do not 
[10]. The most recent zinc acetate trial found no differences between zinc and 
placebo groups in bitter or bad taste or other adverse effects [11]. In their 1984 
study, Eby et al. used a high dose of zinc gluconate, but the lozenges “were not 
bitter, rather they were chalky and bland in taste” [10, p.29]. Concluding from 
other studies with high doses of zinc as zinc lozenges [10], Eby's findings are 
attributable to high doses of zinc rather than the bad taste proposed by Farr and 
Gwaltney [4].
In an extensive Cochrane review that compared placebo arms with 
no-treatment arms, the authors concluded that they “did not find that placebo 
interventions have important clinical effects in general” [12]. Although the 
methodology of controlled trials is important, one should avoid exaggerating the 
role of blinding.
Presenting zinc lozenges and vitamin C for the common cold as examples of 
the placebo effect in action has two unfortunate consequences. First, readers mai 
understand falsely that there is more evidence for the clinical effects of placebo 
than there actually is. Second, readers may understand wrongly that the effects of 
zinc lozenges and vitamin C on the common cold are placebo effects.
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